What determines the temporal sequence of cholinergic dysfunction versus amyloid/tau pathology in human AD?

PARTIALLY ADDRESSED

Despite being the core debate question, causality remains unresolved due to reliance on cross-sectional human data and artificial animal models. The expert noted this chicken-and-egg problem prevents optimal therapeutic targeting strategies. Source: Debate session sess_SDA-2026-04-16-gap-pubmed-20260411-082446-2c1c9e2d (Analysis: SDA-2026-04-16-gap-pubmed-20260411-082446-2c1c9e2d)

Priority: 0.88 Domain: neurodegeneration Hypotheses: 0

📊 Landscape Analysis

Landscape Summary: What determines the temporal sequence of cholinergic dysfunction versus amyloid/tau pathology in human AD? is a 0.88 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.

Key Unanswered Questions

What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

What determines the temporal sequence of cholinergic dysfunction versus amyloid/tau pathology in human AD? — INVOKE-2 (completed)

📈 Living Dashboards

Hypotheses

0.000

Top Score

0.000

Avg Score

Debates

0.65

Avg Quality

60%

Resolution

Mechanistic Families

Gap Resolution Progress60%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

associated with (21)

entities-ros→ADentities-histone-methylation→ADentities-atp7b-gene→ADTAU→ADTDP-43→AD

▸ Show 16 more

APOE→ADMIR-146A→ADAD→TAUSOD1→ADSV2A→ADBnip3→ADtau N-terminal fragments→ADAPOE genotype→ADentities-dian-observational-study→ADentities-ltp→ADentities-neprilysin→ADT2D→ADMICROGLIA→ADAGE→ADPARK7→ADSNCA→AD

biomarker for (1)

tau cleavage products→AD

causes (6)

AD→neurodegenerationPHOSPHORYLATED_TAU→ADBETA_AMYLOID→ADAD→IMMUNE_TOLAD→memory_loss

▸ Show 1 more

AD→DEMENTIA

▸ Show 1 more

levetiracetam→AD

treats (1)

HTL9936→AD

🕑 Activity Feed

✏ update on knowledge_gap by None 2026-04-25T22:15

🎭 What determines the temporal sequence of cholinergic dysfunc q=0.65 2026-04-25T01:03

✏ update on knowledge_gap by None 2026-04-22T19:28

✏ update on knowledge_gap by None 2026-04-22T14:14

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

Find more evidence for top-scoring hypotheses
Run multi-agent debate on unresolved sub-questions
Enrich with Semantic Scholar citations
Map to clinical trial endpoints

← Back to All Gaps

What determines the temporal sequence of cholinergic dysfunction versus amyloid/tau pathology in human AD?

Key Unanswered Questions

Key Researchers

Clinical Trials

Hypothesis Score Distribution

associated with (21)

biomarker for (1)

causes (6)

contributes to (1)

cross disease mechanism in (5)

depleted in (1)

prevents (1)

protective against (1)

regulates (1)

risk factor for (4)

targets (1)

therapeutic target for (6)

treats (1)